• Explore /
  • Poster
  • / A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.

A multicenter, phase II study of trastuzumab plus capecitabine and oxaliplatin (XELOX) as first-line chemotherapy for HER2-positive advanced gastric cancer: Update results of efficacy and toxicity.

Abstract Poster

Authors

null

Jifang Gong

Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing, China

Jifang Gong , Tianshu Liu , Qingxia Fan , Li Bai , Feng Bi , Shukui Qin , Jinwan Wang , Nong Xu , Ying Cheng , Yuxian Bai , Wei Liu , Liwei Wang , Lin Shen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01364493

Citation

J Clin Oncol 32, 2014 (suppl 3; abstr 102)

DOI

10.1200/jco.2014.32.3_suppl.102

Abstract #

102

Poster Bd #

C42

Abstract Disclosures

Similar Posters

Poster

2014 Gastrointestinal Cancers Symposium

Phase II study of trastuzumab in combination with capecitabine and oxaliplatin in patients with advanced gastric cancer.

Phase II study of trastuzumab in combination with capecitabine and oxaliplatin in patients with advanced gastric cancer.

First Author: Min-Hee Ryu

First Author: Yelena Y. Janjigian

First Author: Feng Wang

First Author: Ming-Huang Chen